Reportlinker Adds World Sleep Disorders Market Analysis 2009-2024

Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds World Sleep Disorders Market Analysis 2009-2024

http://www.reportlinker.com/p0135904/Reportlinker-Adds-World-Sleep-Disorders-Market-Analysis-2009-2024.html

Sleep disorders affect hundreds of millions of people worldwide. It is a multi-billion dollar market for drug-based treatments with continuing potential for growth. This new report – World Sleep Disorders Market Analysis 2009-2024 – explains the commercial prospects for drugs to treat sleep disorders, an important, changing pharma market. The principal disorders are insomnia, narcolepsy, sleep apnea and restless leg syndrome, but there are other potentially profitable market segments. Overall, sleep disorders are highly prevalent. Approximately 30% of the population worldwide suffer from sleep disorders analysis suggests. Capturing a segment of this market has enormous potential.

Total drug revenues in the sleep disorders market exceeded $7bn in 2008. The author expects the market to expand during the forecast period 2009-2024 – but by how much? In this new study, you will discover market reach, both worldwide and in major national markets, with leading products and submarkets covered. Growth in the worldwide market will be driven by an increase in the use of insomnia-alleviating and wake-promoting drugs in particular. The treatment of insomnia and some other disorders will change during the forecast period – this report tells you how. An extensive pipeline with new treatment approaches – some close-to-market – will stimulate and increase profitablility in this market sector. A shift from traditional treatments to new drugs will improve treatment options, as well as broadening access to treatments, including use of generic substitutes. New drugs should provide more-attractive treatment options for patients and prescribers who have been deterred by the limitations of existing treatments.

Under-diagnosed and under-treated, sleep disorders present a significant market opportunity for existing and still-to-be-launched treatments. Currently, there is large untapped market potential in the sleep disorder market worldwide. Prescription drugs must compete with OTC products, natural remedies and other treatments, however. Under-treatment is widespread, with many sufferers not seeking medical guidance; that situation should gradually improve, increasing commercial opportunities. The full commercial potential of sleep disorder treatments has thus still to be achieved. The momentum in that sector will increase as companies further invest there, along with healthcare payers worldwide. This new report – Sleep Disorders Market Analysis 2009-2024 – is essential reading for anyone interested in the sleep disorders market. There, you will discover prospects for both existing competitors and potential market entrants from 2009 onwards.

Comprehensive analysis of the sleep disorders market area

Sleep Disorders Market Analysis 2009-2024 examines that market area critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are many tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion to benefit your work.

Why you should buy Sleep Disorders Market Analysis 2009-2024

Benefits from purchasing this report include:

• Your receiving a comprehensive analysis of the prospects for sleep disorder treatments from 2009-2024, including predicted revenues, growth rates and other important data.

• Your accessing forecasts for the top-selling drugs in all the prominent sleep disorder markets, including detailed explanations of factors affecting individual drug sales.

• Your receiving sales forecasts for leading sleep disorder country markets worldwide

• Your identifying key pipeline developments, promising treatment avenues and emerging drug targets.

• Your receiving expert views from our original survey

• Your discovering the important drivers and restraints in the market, and how these operate worldwide

• Your finding out where the market is heading overall – both technologically and commercially – from the present onwards.

There is great untapped potential in the sleep disorder market. Safety and efficacy concerns still limit the commercial potential of sleep disorder drugs, despite the vast potential treatment population – one of the largest in medicine. Some market leaders will soon reach patent expiry. What effects will generic competition have in the market? Will more-effective treatments emerge soon, with commercial gains for innovators? What effects will OTC switching have? This report covers those important questions and many others.

Table of Contents

1 Executive Summary: Sleep Disorders Market Analysis 2009-2024

2 An Introduction to Sleep Disorders

2.1 Sleep Hygiene

2.2 Measuring Sleep

2.3 Circadian Rhythm

2.4 Sleep Disorders

2.4.1 Dyssomnias

2.4.2 Parasomnias

2.5 The Treatment of Sleep Disorders

2.5.1 Therapeutic Approaches

2.5.2 Medical Therapies

2.5.3 Alternative Therapies

2.5.4 OTC Products

2.6 Pharmacological Treatments

2.6.1 Specific Treatments

2.6.2 Off-Label Treatments

3 The Global Sleep Disorder Market Forecast

3.1 The World Market

3.1.1 Growth in the World Sleep Disorder Market to 2012

3.1.2 Growth in the World Sleep Disorder Market from 2013

3.2 The Global Sleep Disorder Market Geographical Breakdown

3.2.1 Sleep Disorder Market Forecast – US

3.2.2 Sleep Disorder Market Forecast – Japan

3.2.3 Sleep Disorder Market Forecast – European Markets

3.2.4 Sleep Disorder Market Forecast – Emerging Markets

4 Insomnia Market Analysis and Forecasts

4.1 The Total Insomnia Market Forecast

4.1.1 Increased Use and Access to Insomnia Treatments Will Drive Market Growth

4.1.2 Pipeline Treatments Will Revive the Insomnia Market

4.2 Ambien Forecast 2009-2024

4.2.1 How Will Generic Competition Impact Upon Ambien Sales?

4.2.2 Will Pipeline Products Make Ambien Treatment Obsolete?

4.3 Lunesta Forecast 2009-2024

4.3.1 Lunesta Will Experience Revenue Growth in the Early Forecast Years

4.3.2 Patent Expiry in 2012 – What Effects?

4.4 Lendormin Forecast 2009-2024

4.4.1 Lendormin Revenues Over the Forecast Period

4.5 Imovane Forecast 2009-2024

4.5.1 How Will Generics and Novel Compounds Affect Imovane Revenues?

4.6 Rozerem Forecast 2009-2024

4.6.1 Will Generic Eszopiclone Seriously Affect Rozerem Sales?

4.6.2 Generic Ramelteon and New Long-Term Treatment Options

4.7 Total Other Insomnia Drugs Market Forecast 2009-2024

4.7.1 Generic Zolpidem – What Effects on Market?

4.7.2 New Pipeline Agents and the Market Entry of More Generic Agents

4.7.3 Generic Ambien CR and Pipeline Products

4.8 Insomnia Market Summary

5 Restless Leg Syndrome Market Analysis and Forecasts

5.1 The Total RLS Market Forecast 2009-2024

5.2 Mirapex Forecast 2009-2024

5.2.1 Patent Expiries and Generic Competition

5.3 Requip Forecast 2009-2024

5.3.1 Competition from Generics and Pipeline Products

5.4 Total Other RLS Drugs Forecast 2009-2024

5.5 RLS Market Forecast Summary

6 Wake-Promoting Drugs Market Analysis and Forecasts

6.1 The Total Wake-Promoting Market Forecast 2009-2024

6.2 Provigil Forecast 2009-2024

6.2.1 How Will Sales of Provigil be Affected by Market Entry of Nuvigil?

6.2.2 Loss of Marketing Exclusivity from 2015

6.2.3 How Competition with Pipeline Agents Will Affect Growth to 2024

6.3 Nuvigil Forecast 2010-2024

6.3.1 Nuvigil Will Experience Consistent Growth from a Large Treatment Base

6.3.2 Growth of Nuvigil Will Slow Due to Entry of New Agents

6.4 Xyrem Forecast 2009-2024

6.4.1 Xyrem Will See Increased Revenues in the Early Forecast Years

6.4.2 New Agents Will Result in Negative Growth in the Later Forecast Years

6.5 Other Wake-Promoting Drugs: Forecast 2009-2024

7 Sleep Disorder Treatments: SWOT Analysis, 2009-2024

7.1 Market Drivers

7.2 Market Restraints

7.3 Current Treatments

7.4 The Large, Competitive Market

7.5 New Insomnia Drugs Will Drive Market Growth

7.6 High Sleep Disorder Prevalence and Unmet Market Needs

7.7 Public Opinion

7.8 Sleep Apnea Market Drivers and Restraints

8 The Sleep Disorder Treatment Pipeline

8.1 Insomnia Treatment Pipeline

8.1.1 Zolpimist (Novadel)

8.1.2 Edluar (Meda)

8.1.3 Silenor (Somaxon)

8.1.4 Indiplon (Neurocrine Biosciences)

8.1.5 Ciltyri (Sanofi-Aventis)

8.1.6 Intermezzo (Transcept)

8.1.7 Almorexant (GSK/Actelion)

8.1.8 Tasimelteon (Vanda)

8.1.9 Medodorm (Essential Nutrition)

8.1.10 Esmirtazapine (Schering-Plough)

8.1.11 Gabitril (Cephalon)

8.1.12 649868 (GSK)

8.1.13 EVT 201 (Evotec)

8.1.14 PD 200390 (Pfizer)

8.1.15 TIK 301 (Tikvah Therapeutics)

8.1.16 HY 10275 (Hypnion)

8.1.17 LY 2624803 (Eli Lilly)

8.1.18 Pruvanserin (Eli Lilly)

8.1.19 MK 4305 (Merck & Co)

8.1.20 TGARO1H (Fabre Kramer)

8.1.21 ITI 007 (Intra-Cellular Therapies)

8.1.22 Staccato Zaleplon (Alexza)

8.1.23 SKP 1041 (Somnus)

8.1.24 Pimavanserin (Acadia)

8.1.25 NBI 75043 (Neurocrine Biosciences)

8.1.26 Adipiplon (Neurogen)

8.1.27 Summary of Promising Late-Stage Insomnia Pipeline Products

8.2 Wake-Promoting Sleep Disorder Treatment Pipeline

8.2.1 Nuvigil (Cephalon)

8.2.2 Tiprolisant (Bioprojet)

8.2.3 CX 717 (Cortex)

8.2.4 VSF 173 (Vanda)

8.2.5 APD 916 (Arena)

8.2.6 COL 204 (CoLucid)

8.2.7 Concluding Thoughts on the Wake-Promoting Pipeline

8.3 Restless Legs Syndrome Treatment Pipeline

8.3.1 NEUPRO (UCB Pharma)

8.3.2 NENAD (Axxonis Pharma AG)

8.3.3 Solzira (Xenoport)

8.3.4 Aplindore (Neurogen)

8.3.5 JZP 7 (Jazz Pharmaceuticals)

8.3.6 Istradefylline (Kyowa Hakko Kirin)

8.3.7 Safinamide (Merck Serono)

8.3.8 Nitisinone (Synosia Therapeutics)

8.3.9 Concluding Notes on the RLS Pipeline

8.4 Sleep Apnea Pharmaceutical Treatment Pipeline

8.4.1 BGC20 0166 (BTG and Collegium)

8.4.2 AVE 0657 (Sanofi-Aventis)

8.4.3 CX 1739 (Cortex)

8.4.4 Gall 200 (Galleon)

8.4.5 Factors Affecting Sleep Apnea Pharmaceutical Market Potential

9 An Expert’s Opinion – Dr. Remy Luthringer

9.1 Unmet Needs in the Treatment of Sleep Disorders

9.2 The Future of the Wake-Promoting Market

9.3 The Insomnia Market

9.4 Long-Term and Off-Label Use of Insomnia Treatments

9.5 The Sleep Disorder Pipeline

9.6 The Evolution of Sleep Disorder Treatments

9.7 Growth in the Sleep Disorder Market

10 Conclusions

10.1 Sleep Disorders Constitute a Large Market Opportunity

10.2 The World Market for Sleep Disorder Treatments Will Grow Over the Forecast Period

10.3 The Global Market Distribution Will Change over the Forecast Period

10.4 The Insomnia Treatment Market

10.5 Restless Leg Syndrome Treatment Market

10.6 The Wake-Promoting Drug Market

10.7 Drivers and Restraints

10.8 The Sleep Disorder Treatment Pipeline Overview

10.8.1 Insomnia Pipeline

10.8.2 Wake-Promoting Pipeline

10.8.3 Restless Legs Syndrome Pipeline

10.8.4 Sleep Apnea Pipeline

List of Tables

Table 2.1 Dyssomnia Sleep Disorders

Table 2.2 Parasomnia Sleep Disorders

Table 3.1 Global Sleep Disorder Market Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 3.2 Sleep Disorder Comparative Forecast Sales ($m), 2009-2024

Table 3.3 Sleep Disorder Comparative Forecast by Market Share (%), 2009-2024

Table 3.4 Geographical Market Share (%) Forecast to 2024

Table 3.5 Geographical Sales ($m) Forecast to 2024

Table 4.1 Total Insomnia Market Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.2 Ambien Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.3 Lunesta Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.4 Lendormin Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.5 Imovane Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.6 Rozerem Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.7 Total Other Insomnia Drugs Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 4.8 Insomnia Drug Market Share (%) Comparative Forecast, 2009-2024

Table 5.1 Total RLS Market Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 5.2 Mirapex Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 5.3 Requip Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 5.4 Total Other RLS Drugs Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 5.5 RLS Drug Market Share (%) Comparative Forecast, 2009-2024

Table 6.1 Total Wake-Promoting Market Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 6.2 Provigil Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 6.3 Nuvigil Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 6.4 Xyrem Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 6.5 Total Other Wake-Promoting Drugs Forecast Sales ($m), Growth (%) and CAGR (%), 2009-2024

Table 7.1 A SWOT Analysis of the Sleep Disorder Market, 2009-2024

Table 8.1 The Insomnia Treatment Pipeline, 2009

Table 8.2 The Wake-Promoting Sleep Disorder Treatment Pipeline, 2009

Table 8.3 The RLS Treatment Pipeline, 2009

Table 8.4 The Sleep Apnea Pharmaceutical Treatment Pipeline, 2009

List of Figures

Figure 3.1 Global Sleep Disorder Market Sales ($m), 2009-2024

Figure 3.2 Sleep Disorder Comparative Forecast in Sales ($m), 2009-2024

Figure 3.3 Sleep Disorder Comparative Forecast by Market Share (%), 2009-2024

Figure 3.4 Global Market Share (%) Comparison, 2008

Figure 3.5 Global Market Share (%) Comparison, 2024

Figure 3.6 US Sleep Disorder Market Sales ($m) to 2024

Figure 3.7 Japan Sleep Disorder Market Sales ($m) to 2024

Figure 3.8 Europe Sleep Disorder Market Sales ($m) to 2024

Figure 3.9 Emerging Markets Sleep Disorder Market Sales ($m) to 2024

Figure 4.1 Total Insomnia Market Sales ($m), 2009-2024

Figure 4.2 Ambien Sales ($m), 2009-2024

Figure 4.3 Lunesta Sales ($m), 2009-2024

Figure 4.4 Lendormin Sales ($m), 2009-2024

Figure 4.5 Imovane Sales ($m), 2009-2024

Figure 4.6 Rozerem Sales ($m), 2009-2024

Figure 4.7 Total Other Insomnia Drugs Sales ($m), 2009-2024

Figure 4.8 Comparative Insomnia Forecast in Sales ($m), 2009-2024

Figure 4.9 Comparative Insomnia Forecast by Market Share (%), 2009-2024

Figure 5.1 Total RLS Market Sales ($m), 2009-2024

Figure 5.2 Mirapex Sales ($m), 2009-2024

Figure 5.3 Requip Sales ($m), 2009-2024

Figure 5.4 Total Other RLS Drugs Sales ($m), 2009-2024

Figure 5.5 Comparative RLS Forecast in Sales ($m), 2009-2024

Figure 5.6 Comparative RLS Forecast by Market Share (%), 2009-2024

Figure 6.1 Total Wake-Promoting Market Sales ($m), 2009-2024

Figure 6.2 Provigil Sales ($m), 2009-2024

Figure 6.3 Nuvigil Sales ($m), 2009-2024

Figure 6.4 Xyrem Sales ($m), 2009-2024

Figure 6.5 Total Other Wake-Promoting Drugs Sales ($m), 2015-2024

Figure 10.1 Global Sleep Disorder Market Sales ($m), 2009-2024

Figure 10.2 Sleep Disorder Comparative Forecast Sales ($m), 2009-2024

Figure 10.3 Total Insomnia Market Sales ($m), 2009-2024

Figure 10.4 Total RLS Market Sales ($m), 2009-2024

Figure 10.5 Total Wake-Promoting Market Sales ($m), 2009-2024

Companies Listed

Acadia

Actavis

Actelion

Alexza

Apotex

Arena

Astellas

Axxonis Pharma AG

Barr

Bayer

Bioprojet

Boehringer Ingelheim

BTG

Cephalon

Collegium

CoLucid

Cortex

Daiichi Sankyo

Eisai

Eli Lilly

Essential Nutrition

Evotec

Fabre Kramer

Forenap Pharma

Galleon

GlaxoSmithKline

Hypnion

Intra-Cellular Therapies

Italfarmaco

Jazz Pharmaceuticals

Kyowa Hakko Kirin

Meda

Merck & Co

Merck Serono

Mylan

Neurocrine Biosciences

Neurogen

Novadel

Orexo

Pfizer

Pharmascience

Ranbaxy

Sanofi-Aventis

Schering-Plough

Sepracor

SkyePharma

Somaxon

Somnus

Strada

Synosia Therapeutics

Takeda

Teva

Tikvah Therapeutics

Transcept

UCB Pharma

Valeant

Vanda

Watson

Wyeth

Xenoport

Latest Headlines

• CPAP treatment is best for elderly sleep apnea patients
• Sleep apnea awareness
• Obstructive sleep apnea linked to cancer growth in mice
• Sleep apnea linked to bedwetting
• Novel therapy improves cardiovascular health in central sleep apnea patients
• Sleep apnea: a growing health concern
• Sleep Apnea Patients Unable to Tolerate CPAP Or Any Device? – A New Conservative Hope Available Now
• Insomnia linked to high insulin resistance in diabetics
• Philips displays sleep therapy products in Dubai
• The risks of sleep apnea
• AZ-TMJ – Now Reaching Even More Patients with Their Effective Sleep Apnea Treatments
• Pro baseball player gets sidelined due to sleep disorder
• The CPAP Shop Introduces New FREE eBook For CPAP Machine Users
• Sleep loss leads to greater appetite
• Sleepless elites far from grumpy and tired

In The News

Sleep loss boosts optimism and limits negative thinking

New research is looking into the

New drug funding for narcoleptic New Zealanders

Pharmac, New Zealand’s only agency under

Sleeping on your side may help prevent snoring

According to scientists, there are two

Sleep patient dies during study

What was expected to be a

Daytime sleep detrimental to shift workers

Humans are naturally day creatures. However,